23e Nationale Longkanker Symposium 2022
Welcome + Quiz
Combo IO-CT in NSCLC in stage IV
Martin Reck, MD, PhD, is head of the Department of Thoracic Oncology and head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany.
He is also Principal Investigator in the Airway Research Center North (ARCN), which is a member of the German Centre for Lung Research (DZL).
Dr Reck has been a Principal Investigator (PI) in various clinical trials since 1993. His main interests are new medical treatments of thoracic malignancies as well as translational research related to predictive markers. A particular focus of his work has been attributed to the clinical development of antiangiogenic compounds. Recently he also has been deeply involved in several key trials with immunotherapies including ipilimumab, PD-1 and PDL-1 antibodies and other agents. As part of this activity he has been the principal investigator of the Keynote 24 trial investigating monotherapy with Pembrolizumab against platinum based chemotherapy in untreated patients with advanced PDL-1 expressing NSCLC (TPS =/> 50%), IMpower 150 trial and the CheckMate 9LA trial, which evaluated the combination of Nivolumab and Ipilimumab together with a short chemotherapy. Furthermore he has served on various Global Trial Steering Committees.
Besides the European Society of Medical Oncology (ESMO) Dr Reck is member of the International Association for the study of Lung Cancer (IASLC), the American society of Medical Oncology (ASCO), the German Working Group for Lung Cancer, the German Cancer Society (DKG) and the German Society of Pulmonology (DGP).
He has published papers in numerous peer-reviewed journals and is member of the editorial board of Journal of Thoracic Oncology, Annals of Oncology and Lung Cancer.
The implementation of immunotherapies has significantly improved our opportunities to treat non oncogenic driven advanced non-small cell lung cancer (NSCLC). I will discuss the most recent data for the novel opportunity to use double immunotherapy combinations as first-line treatment.
Therapeutic options after first-line triple therapy
Prof. Fabrice Barlesi, General Director, Gustave Roussy, France
Le Pr Fabrice Barlesi est Directeur Général au sein de l’institut Gustave Roussy. C’est un des acteurs majeurs de la recherche sur les thérapies innovantes contre le cancer. Il a cofondé le cluster français de l’immunologie Marseille Immunopôle dont la mission est de rassembler les expertises en immunologie de la métropole d’Aix-Marseille. Le Pr Barlesi est auteur et co-auteur de près de 400 publications parues dans des revues internationales ou des ouvrages spécialisés. En 2018, la Société européenne d’oncologie médicale (ESMO) et l’Association internationale pour l’étude du cancer du poumon (IASLC) lui ont décerné le prestigieux prix Heine H. Hansen. Fabrice Barlesi figure dans la liste des chercheurs les plus influents au monde (Highly cited researchers de Web of Science Group).
IO therapy beyond PD-(L)1
Prof. John B. Haanen
John Haanen finished his MD at Leiden University cum laude in 1988. From 1988 till 1991 he performed his PhD studies at the Division of Immunohematology & Blood Bank of Leiden University Medical Center and at DNAX, Research Institute, Palo Alto, California, US and defended his PhD thesis on human CD4+ helper T cells reactive against mycobacteria. He trained in internal medicine in hospitals in Leiden and The Hague. In 1996 he was registered as consultant internist. From 1997-1999 he did a post-doctoral fellowship at the Division of Immunology of the Netherlands Cancer Institute (NKI), Amsterdam. From 1999-2001 he trained in medical oncology and was appointed a permanent position as consultant medical
oncologist and research group leader at NKI. His research has been focused on development of innovative immunotherapies in close collaboration with prof. Ton Schumacher. In 2008 he was appointed professor of translational immunotherapy of cancer at Leiden University Medical Center. From 2009 till 2018 he headed the Division of Medical Oncology at NKI. In 2018 he was appointed CSO Immunotherapy, one of the major research themes at NKI. His current research is on development of cellular therapies for solid tumors, neoadjuvant immunotherapies, and biomarker research. His clinical specialty is in melanoma and other skin cancers, kidney cancer and management of immune-related adverse events. He coauthored over 300 peer-reviewed articles, serves at the editorial board of ESMO Open, Cancer Treatment Reviews and Kidney Cancer. He is currently Editor-in-Chief of ESMO IOTECH. John Haanen was scientific co-chair of ESMO IO Congress from 2016-2019, and Scientific Chair of the ESMO 2020 Congress.
Neo-adjuvant therapies in resectable stages
Prof. Dr. Martin Schuler, Director Department Of Medical Oncology, University Hospital Essen
Martin Schuler, MD, is director of the Department of Medical Oncology and vice director for translational research of the West German Cancer Center in Essen, Germany, which is the comprehensive cancer center of the University Hospital Essen and one of 13 Oncology Centers of Excellence designated by the German Cancer Aid. Professor Schuler also heads the partner site Essen/Düsseldorf of the German Cancer Consortium (DKTK). He holds a full professorship of medicine at Medical Faculty of the University Duisburg-Essen. Professor Schuler received his medical degree from Johannes Gutenberg University of Mainz, Germany, and completed his residency and fellowships in internal medicine, hematology/medical oncology, and pulmonary medicine at the University Medical Center in Mainz. He also completed a postdoctoral fellowship with Dr. Douglas R. Green at the Division of Cellular Immunology at La Jolla Institute for Allergy and Immunology in San Diego, California.
Professor Schuler is board certified in internal medicine, hematology/medical oncology, pulmonary medicine, and palliative medicine. He is a member of several professional associations, including the German Society of Hematology and Oncology, the German Society of Pulmonary Medicine, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. Professor Schuler sits on the editorial boards of several scientific journals, including Oncogene, the Journal of Cancer Research and Clinical Oncology, and Oncology Research and Treatment. He has authored or co-authored more than 100 original articles published in peer-reviewed journals such as Cancer Cell, Science, Nature, the New England Journal of Medicine, Lancet Oncology and the Journal of Clinical Oncology. Professor Schuler has received several awards including the AIO Scientific Award of the German Cancer Society and the Pulmedica Award of the German Society for Pulmonary and Respiratory Research.
IO strategies in stage III NSCLC
Medical Crossfire 1: IO monotherapy in PD-L1 >50% is first choice Chemo-IO in PD-L1 >50% is the first choice
Michel vd Heuvel & Fabrice Barlesi
Vaccines for lung cancer
Prof. Dr. Joachim Aerts, Head of the Department, Professor of Pulmonary Medicine, Erasmus University Medical Center Rotterdam
Joachim Aerts is head of the department of Pulmonary Medicine at the Erasmus University Medical Center Rotterdam since 2018. His main research focus is on fundamental, translational and clinical research in immuno oncology, with a strong focus on lung cancer and mesothelioma. As PI and as co-investigator, prof. Aerts is involved in many studies both human and animal.
Prof. Aerts is leader of the core network on mesothelioma and board member of the European Reference Network on Rare Respiratory Diseases (ERN-Lung) and elected member of the board of directors of the International Association for the Study of Lung Cancer (IASLC). He is a frequent invited speaker on international conferences, and he is scientific committee member of multiple national and international societies, such as the NVALT, EORTC, ASCO, ESMO, ETOP, AACR, ERS and ATS. Prof. Aerts is co-author of >200 articles in international peer reviewed scientific journals.
Vera Bonta Award
MPM treatment in the IO era
EGFR, ALK and KRAS
How to find these drivers in tumor tissue and ctDNA
Michel van den Heuvel
How to discuss the results in a molecular tumor board
Antibody-drug conjugates in 2022
Medical Crossfire 2 MET exon 14 skipping mutations: Chemo is first choice Targeted agents is first choice
Egbert Smit & Pasi Janne